International immunopharmacology
Recent research progress in structural optimization and cancer treatment of novel selective FGFR inhibitors (2020-2025).
Rongfei Liu, Jinghui Qi, Yue Liu, Mingyue Hou, Mingyu Zhang, Xuan An, Jinxing Hu
Published: 202610.1016/j.intimp.2026.116249
Abstract
Abnormalities in protein tyrosine kinases (PTKs) are one of the primary drivers of cancer. As a receptor subfamily, fibroblast growth factor receptors (FGFRs) comprise four subtypes-FGFR1 to FGFR4. Their abnormal intracellular expression is a signifi…
Preview only. Read the full abstract at the source